EGFR_IUO 3.20 Clinical Study Protocol

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2023

Primary Completion Date

December 18, 2023

Study Completion Date

December 18, 2023

Conditions
NSCLC
Interventions
DEVICE

Idylla EGFR_IUO/3.20 Mutation Test

Clinical Performance Study Protocol for Idylla EGFR\_IUO/3.20 Mutation Test The EGFR\_IUO/3.20 is automated on the Idylla™ Platform, which executes the entire process from sample to result including sample liquefaction, cell lysis, real-time PCR amplification/detection, and data analysis and reporting.

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Biocartis NV

INDUSTRY